Faron Pharmaceuticals Oy Share Discussion Threads

[soulected] 04/8/2023 22:32

Starting to wake up at last, looking good for a further rise, lots of positive news released with more due!

[mcbull] 16/1/2023 11:04

From a 25% 5 year survival to 2 out of 3 previously refractory to other treatments, and now with reduction of blasts........this is a game changer, especially in myelodysplastic syndrome.

[soulected] 16/1/2023 09:24

More great progress, this is very promising!BEXMAB Study Update -- Objective response observed in 3 out of 5 patients in the first doublet cohort -- 2 of the 3 responders were refractory to prior azacitidine monotherapy -- No additional adverse events observed adding bexmarilimab to standard of care -- Rapid enrollment into both doublet and triplet combinations

[soulected] 07/12/2022 09:01

What's moving it this morning?

[hashertu] 05/12/2022 10:20

Another step in (what appears to be) the right direction.
Next year could be very interesting, especially if more centres come forward.
Are there any known manufacturing, or distribution, limitations of Bexmab at the moment?

[share23] 28/11/2022 13:32

https://www.redeye.se/video/event-presentation/865582/faron-pharmaceuticals-infocus-interview-with-ceo-markku-jalkanen-at-redeye-life-science-day-2022?utm_source=video&utm_medium=email

[share23] 24/11/2022 07:06

https://www.redeye.se/video/company-prerecorded-presentation/864997/faron-pharmaceuticals?searchResult=851e838b-e0bc-3ce8-93ed-a993eddb15fb&query=&fromPage=SAVED

[soulected] 16/11/2022 12:17

Yes, it is looking very good - about time!

[raldo] 16/11/2022 07:32

A lovely quiet board, but things starting to happen in the background for Faron?

[share23] 18/10/2022 18:39

https://www.faron.com/sites/default/files/2022-06/Investment%20Case%20verification%20deck%20CLEAN%2013.10.2022.pptx

[hashertu] 15/6/2022 19:48

I wonder if they now know who will respond to treatment before the drug is given.
Also, if the response rate would be higher if given to less ill patients whose immune system can still be stimulated into action.
Time will tell.
Notwithstanding, with my limited understanding of the science, the results look impressive.

[share23] 25/4/2022 13:58

New job ad from Faron. Director of Finance. According to job description: " The goal is to elevate and develop the processes to level accepted by the SEC in case of a potential US listing".Key responsibilities-Lead PCAOB uplift in preparation for a potential US listing together with external advisors-Be part of the "IPO" teamhttps://www.faron.com/sites/default/files/Director%20of%20Finance%20www-sivut%20250422.pdf

[share23] 23/4/2022 17:56

Faron latest presentation. CFO mentions that they have hired new VP of investor relations to New York and that they are making Faron Wallstreet ready. Are they getting ready for an IPO to Nasdaq, New York? (around 4:00 minutes)Additionally CEO talks about potential licensing deal for Bexmarilimab and refers to other deals that have been made in the area which are billion-dollar milestone deals. CEO also says after mentioning the billion dollar deals: Happy to say there are number of companies discussing with us (around 19:00 minutes).Can't believe this company is so under the radar with so low share price.https://faron.videosync.fi/agm_2022_presentation_ceo_and_cfo

[davidlloyd] 23/2/2022 12:29

Worth adding here at these levels IMHO, and have done 😀. Looking forward to hearing the webcast.
DL

[hashertu] 23/2/2022 10:34

It does sound promising.
But trying to make sense of the statistics is a step too far, for me, without more explanation.

[raldo] 23/2/2022 07:45

Nice RNS Faron!

[hashertu] 10/12/2021 10:12

Yesterday's news. Another small step in the right direction.

[share23] 23/9/2021 10:44

Faron seems to have busy time ahead:https://www.g20innovationleague.com/azienda/faron-pharmaceuticals-oyhttps://macrophage-directed-therapies.com/speaker/maija-hollmen/https://macrophage-directed-therapies.com/speaker/juho-jalkanen/

[share23] 21/9/2021 18:12

Updated corporate presentation from Faron. Lots of interesting reeding.https://www.faron.com/sites/default/files/Corporate%20Deck%20SEP%202021.pdf

[share23] 18/9/2021 12:09

https://dailyreporter.esmo.org/esmo-congress-2021/drug-development/bexmarilimab-monotherapy-shows-promising-anti-tumour-activity-in-advanced-solid-tumours

[hashertu] 17/9/2021 11:08

"The efficacy and survival data are particularly compelling when you consider the late-stage, treatment-refractory disease patient population and inclusion of nonimmunogenic cold tumors in the trial."

A fairly bullish statement from the principal investigator!
Again, no nasties coming out of the woodwork.

I wonder when they hope to move to earlier stage patients who (probably) have less compromised immune systes.

[share23] 17/9/2021 07:23

Breast cancer seems to be new responder group with 4/10. According to WHO 2.3 million new breast cancer cases was detected in 2020. About 80% of these seems to be ER+. Huge market.https://www.who.int/news-room/fact-sheets/detail/breast-cancerhttps://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive

[waterloo01] 17/9/2021 06:13

On 1st pass data looks good

Landmark OS analysis of Part I/II patients who received three courses of treatment and had their scheduled tumor imaging at cycle four (n=91) estimated that 83% of patients achieving disease control rate (DCR) status were alive at six months after the landmark (approximately 240 days from initiation of treatment) compared to 29% of non-DCR patients. The most significant disease control rate (DCR) among Part II cohorts was observed in cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%), hepatocellular carcinoma (40%) and breast cancer (40%) patients.